2篇
您的检索式：作者名="Yafang Lou"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia显示文摘一个 CALLG2008 协议被中国尖锐成淋巴细胞的白血病合作的组为成年尖锐成淋巴细胞的白血病(所有) 开发。我们回顾地与费城染色体(Ph ) 分析了 153 个最新诊断的成年病人积极加在 2009 和 2015 之间的 CALLG2008 政体注册进 imatinib (400 mg/d ) 的所有。中部的年龄是 40 年(范围, 1868 年) ,与 81 (52.3%) 男性。全面 hematologic 完全的宽恕(CR ) 率在正式就职以后是 96.7% 。与 24.2 个月的中部的后续,估计的 3 年的全面幸存(OS ) 和没有事件的幸存(EFS ) 评价是 49.5%(95% 信心间隔(CI ) :38.5%59.5%) 并且 49.2%(95% CI:38.3%59.2%) 分别地。58 (36 与 haploidentical 施主) 病人们经历了 allogeneic 在第一 CR 的造血的干细胞移植(allo-HSCT ) 。在在在正式就职以后的 CR1 的病人之中, 3 年的 OS 和 EFS 比在 without allo-HSCT 组在 allo-HSCT 组显著地更好(73.2% , 95% CI:58.3%83.5% 对 22.2% , 95% CI:8.7%39.6% 并且 66.5% , 95% CI:50.7%78.2% 对 16.1% , 95% CI:5.1%32.7% ,分别地) 。Multivariate 分析显示出那 allo-HSCT,主要分子的反应的成就独立地与有利 OS 或 EFS 被联系。在 allo-HSCT 队,有趣地,施主类型(haploidentical 对匹配的施主) 没在 EFS 或 OS 上有重要影响。所有这些结果建议加 CALLG2008 的那 imatinib 是一个有效协议为 Ph 积极所有。Haploidentical 施主能也是一个合理其他的有用施主水池。 | Yinjun Lou Yafang Ma Chenyin Li Sansan Suo Hongyan Tong Wenbin Qian Wenyuan Mai Haitao Meng Wenjuan Yu Liping Mao Juyin Wei Weilei Xu Jie Jin | 2017 | Frontiers of Medicine2017，11，2： | 3 |
| 2 | Correlation of ARNTL2 with Immune Infiltration and Its Role as a Potential Prognostic Biomarker in Lung Adenocarcinoma显示文摘Background:ARNTL2 is a core component of the circadian clock genes and plays regulatory roles in the cell cycle and immune infiltration,but its mechanism in lung cancer(LC)remains unclear.Objective:To investigate the clinical and therapeutic value of ARNTL2 in LC.Methods:The Oncomine and Cancer Cell Line Encyclopedia(CCLE)databases were adopted for assessing the ARNTL2 expression,after which the Kaplan-Meier plotter and Gene Expression Profiling Interactive Analysis 2(GEPIA2)databases were used to assess the correlation of ARNTL2 with prognosis.The univariate and multi-variate Cox regression analyses were utilized to identify independent prognostic factors.Also,we explored how ARNTL2 expression is related to immune infiltration,and immunomodulators in non-small lung cancer(NSCLC)using the Tumor Immune Estimation Resource(TIMER)database,TISIDB database and Gene Set Enrichment Analysis(GSEA).Finally,coexpression of ARNTL2 and PD-L1 in lung adenocarcinoma(LUAD)was verified via immunofluorescence staining and COXPRESdb v7 database.Results:Our study demonstrated a remarkable upregulated expression of ARNTL2 in multiple cell lines and can-cers,including NSCLC.Prognostic analysis displayed a remarkable correlation between high ARNTL2 expression and unfavorable overall survival(OS)and first progressive(FP)survival among patients ailing from LUAD,and ARNTL2 was an independent predictor of prognosis for LUAD patients.GSEA analysis showed that overexpres-sion of ARNTL2 was significantly linked with cell cycle and immunity.Furthermore,we reported a correlation of ARNTL2 expression with immunomodulators and lymphocytes.Immunofluorescence staining revealed that ARNTL2 and PD-L1 were elevated relative to normal tissue for LUAD,and colocalization of them was observed.Conclusion:Elevated ARNTL2 expression in LUAD revealed the prognostic values and its prospective role as a target for cell cycle and immune therapy. | Junjie Pan Hongkuan Yang Lihong Zhu Yafang Lou | 2021 | Clinical Complementary Medicine and Pharmacology2021，1，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员